Skip to main content
. 2018 Mar 27;46(10):5029–5049. doi: 10.1093/nar/gky227

Figure 5.

Figure 5.

(A–C) Cell extracts from DMSO (D) or melphalan (M)-treated C33A2 cells were subjected to immunoprecipitation with the antibodies to BRCA1, phosphorylated BRCA1 (p-BRCA1) or BCLAF1, followed by western blotting with antibodies to U2AF65, SF3b or BCLAF1. The levels of immunoprecipitated protein and the levels of each protein in the input extracts were quantified. Percent of input protein immunoprecipitated by each antibody in extracts from in DMSO or melphalan treated cells are shown below each gel. (D and E) ChIP analyses on C33A2 cells using antibodies to proteins indicated in each histogram and qPCR of the indicated amplicons. Mean values with standard deviations of the amount of immunoprecipitated DNA compared to DNA from DMSO treated cells are displayed. Chip extracts were prepared from C33A2 cells treated with melphalan for the indicated time-periods. (F) Western blot on BCLALF1 in C33A2 cells or C33A2 cells treated with DMSO or melphalan for the indicated time points. BCLAF1 levels were normalized to actin and BCLAF1 over actin in untreated cells was set as 1.